Features of early pregnancy treatment in women with luteal phase defect

Abstract

The purpose of this study was the first pregnancy trimester flow analysis in patients with IDLF receiving pre-gravidity training including dydrogesterone taking. Materials and methods. The drug was prescribed to 60 patients at the pregnancy planning stage. After becoming pregnant patients were divided into two clinical groups: I – with dydrogesterone prolongation taking in trimester one (n = 36), II – dydrogesterone cessation after pregnancy verification (n = 24). The results overview. Significant differences in the incidence of adverse prenatal outcomes, with a predominance of those in clinical group II were obtained. Conclusion. Dydrogesterone discontinuation for up to 8 weeks of pregnancy, when used at the stage of preparation is irrational, as manifested not only as a threat, but the termination of pregnancy in the I trimester.

Keywords

• pregnancy
• threat of miscarriage
• dydrogesterone